American Biotech Needs a Coordinated Strategy to Counter China's Ambitions

China has unveiled a new five-year strategy, designating biotechnology as a foundational national industry. This ambitious declaration aims to surpass the United States as the global leader in biotech innovation, presenting a direct challenge to a sector vital for American competitiveness. The U.S. must respond with a robust, integrated approach to protect its strategic advantage.

The American biotechnology sector is a cornerstone of the nation's prosperity, providing nearly 10 million jobs and generating over trillion in annual economic activity. Beyond its economic contributions, it is instrumental in developing advanced manufacturing, ensuring access to life-saving medicines, and bolstering defenses against pandemics and biological threats. A decline in U.S. biotech leadership would have severe repercussions for both its economic stability and national security. Maintaining this leadership requires a holistic strategy, encompassing support for university research, nurturing startups, strengthening trial networks, and enhancing manufacturing capabilities to foster a resilient biotech ecosystem.

To preserve its preeminence in biotechnology, the United States must act decisively. This involves not only direct investment but also fostering an environment that encourages continuous innovation and collaboration across all facets of the biotech landscape. By strategically supporting the entire ecosystem, the U.S. can ensure its continued dominance in this critical field, safeguarding both its economy and national security against emerging global competition.